Comparative Efficacy and Safety of Transcatheter Mitral Valve Repair Versus Mitral-valve Surgery in Elderly Patients With Mitral Regurgitation: A Systematic Review and Meta-analysis.

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Journal of the Saudi Heart Association Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI:10.37616/2212-5043.1399
Saif Almuzainy, Mohamed Lemine, Rayan Aljubeh, Sami Alsalem
{"title":"Comparative Efficacy and Safety of Transcatheter Mitral Valve Repair Versus Mitral-valve Surgery in Elderly Patients With Mitral Regurgitation: A Systematic Review and Meta-analysis.","authors":"Saif Almuzainy, Mohamed Lemine, Rayan Aljubeh, Sami Alsalem","doi":"10.37616/2212-5043.1399","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Mitral valve surgery is the reference treatment for severe symptomatic mitral regurgitation (MR). Percutaneous mitral valve interventions, such as the MitraClip procedure, offer an alternative, particularly for high-risk patients. The aim of this systematic review and meta-analysis was to analyze the safety and effectiveness of transcatheter mitral valve repair (TMVR) compared to surgical mitral valve repair or replacement (SMVR) in elderly patients with mitral regurgitation.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Ovid, EBSCO, and ProQuest through July 2024. Eligible studies were randomized controlled trials and observational comparative studies of TMVR versus SMVR for patients with MR, reporting outcomes such as all-cause mortality, MR recurrence, stroke, myocardial infarction, and length of stay (LOS). Statistical analyses were performed using RevMan.</p><p><strong>Results: </strong>Our search identified 3166 records, with 2756 screened and 21 studies included after review. The studies, comprising 20 retrospective cohorts and 1 randomized controlled trial with 20,900 patients, compared TMVR to SMVR. TMVR patients were significantly older than SMVR patients (MD 3.44 years; P < 0.00001). Mortality rates were similar at 30 days (relative risk (RR) 1.08; P = 0.79) and one year (RR 1.27; P = 0.18), but SMVR showed lower mortality at three years (RR 1.82; P = 0.006). SMVR also significantly reduced MR ≥ 3+ recurrence at 30 days (RR 6.95; P < 0.00001), one year (RR 3.31; P = 0.0001), and three years (RR 4.37; P < 0.00001). TMVR was associated with higher myocardial infarction rates (RR 1.58; P = 0.02) but reduced LOS (MD -4.88 days; P < 0.00001). Sensitivity analysis showed consistent results for recurrence of MR ≥ 3+ and variable outcomes for other metrics. Evidence of publication bias was noted for mortality at 30 days and LOS.</p><p><strong>Conclusion: </strong>While TMVR with the MitraClip offers shorter hospital stays and is less invasive, SMVR provides better long-term survival and lower MR recurrence rates, emphasizing the need for a tailored approach based on patient risk profiles.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 4","pages":"316-334"},"PeriodicalIF":0.7000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Saudi Heart Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37616/2212-5043.1399","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Mitral valve surgery is the reference treatment for severe symptomatic mitral regurgitation (MR). Percutaneous mitral valve interventions, such as the MitraClip procedure, offer an alternative, particularly for high-risk patients. The aim of this systematic review and meta-analysis was to analyze the safety and effectiveness of transcatheter mitral valve repair (TMVR) compared to surgical mitral valve repair or replacement (SMVR) in elderly patients with mitral regurgitation.

Methods: We searched PubMed, Scopus, Ovid, EBSCO, and ProQuest through July 2024. Eligible studies were randomized controlled trials and observational comparative studies of TMVR versus SMVR for patients with MR, reporting outcomes such as all-cause mortality, MR recurrence, stroke, myocardial infarction, and length of stay (LOS). Statistical analyses were performed using RevMan.

Results: Our search identified 3166 records, with 2756 screened and 21 studies included after review. The studies, comprising 20 retrospective cohorts and 1 randomized controlled trial with 20,900 patients, compared TMVR to SMVR. TMVR patients were significantly older than SMVR patients (MD 3.44 years; P < 0.00001). Mortality rates were similar at 30 days (relative risk (RR) 1.08; P = 0.79) and one year (RR 1.27; P = 0.18), but SMVR showed lower mortality at three years (RR 1.82; P = 0.006). SMVR also significantly reduced MR ≥ 3+ recurrence at 30 days (RR 6.95; P < 0.00001), one year (RR 3.31; P = 0.0001), and three years (RR 4.37; P < 0.00001). TMVR was associated with higher myocardial infarction rates (RR 1.58; P = 0.02) but reduced LOS (MD -4.88 days; P < 0.00001). Sensitivity analysis showed consistent results for recurrence of MR ≥ 3+ and variable outcomes for other metrics. Evidence of publication bias was noted for mortality at 30 days and LOS.

Conclusion: While TMVR with the MitraClip offers shorter hospital stays and is less invasive, SMVR provides better long-term survival and lower MR recurrence rates, emphasizing the need for a tailored approach based on patient risk profiles.

经导管二尖瓣修复术与二尖瓣手术在老年二尖瓣反流患者中的疗效和安全性比较:系统综述与元分析》。
目的:二尖瓣手术是治疗严重症状性二尖瓣反流(MR)的首选方法。经皮二尖瓣介入治疗,如 MitraClip 手术,提供了一种替代方法,尤其适用于高风险患者。本系统综述和荟萃分析旨在分析经导管二尖瓣修复术(TMVR)与手术二尖瓣修复或置换术(SMVR)相比,在二尖瓣反流老年患者中的安全性和有效性:我们检索了截止到 2024 年 7 月的 PubMed、Scopus、Ovid、EBSCO 和 ProQuest。符合条件的研究是针对二尖瓣反流患者的 TMVR 与 SMVR 的随机对照试验和观察性比较研究,报告的结果包括全因死亡率、二尖瓣反流复发率、中风、心肌梗死和住院时间(LOS)。统计分析使用 RevMan 进行:我们的搜索发现了 3166 条记录,筛选出 2756 条记录,经审查后纳入了 21 项研究。这些研究包括20项回顾性队列研究和1项随机对照试验,共有20900名患者接受了TMVR和SMVR治疗。TMVR患者的年龄明显大于SMVR患者(MD 3.44岁;P < 0.00001)。30 天(相对风险 (RR) 1.08;P = 0.79)和一年(RR 1.27;P = 0.18)的死亡率相似,但 SMVR 三年后的死亡率较低(RR 1.82;P = 0.006)。SMVR 还能明显降低 MR ≥ 3+ 在 30 天(RR 6.95;P < 0.00001)、一年(RR 3.31;P = 0.0001)和三年(RR 4.37;P < 0.00001)的复发率。TMVR 与较高的心肌梗死发生率相关(RR 1.58;P = 0.02),但缩短了 LOS(MD -4.88 天;P < 0.00001)。敏感性分析显示,MR≥3+复发的结果一致,而其他指标的结果不一。30天死亡率和LOS有发表偏倚的证据:结论:使用MitraClip进行TMVR的住院时间更短,创伤更小,而SMVR的长期存活率更高,MR复发率更低,因此需要根据患者的风险特征量身定制治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the Saudi Heart Association
Journal of the Saudi Heart Association CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.40
自引率
0.00%
发文量
30
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信